Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers
BioSpace
Mon, 11/14/22 - 10:59 am
Tags:
biotech, biopharma, employers, corporate culture, Moderna Therapeutics, Genentech, Pfizer, Amgen, AbbVie
AbbVie Touts Subgroup Data in Phase II Atrial Fibrillation Miss
BioSpace
Tue, 11/8/22 - 11:04 am
Tags:
AbbVie, AGN-151607, atrial fibrillation, clinicla trials
This Biopharma Offspring Is All Grown Up
Medical Devices and Diagnostics Industry
Tue, 11/8/22 - 10:48 am
Tags:
Abbott Labs, spinoffs, AbbVie
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
BioSpace
Tue, 11/1/22 - 11:04 am
Tags:
AbbVie, cedirogant, Skyrizi, Rinvoq, Humira
AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others
Endpoints
Mon, 10/31/22 - 04:22 pm
Tags:
AbbVie, Orilissa, generics, Sandoz, Teva Pharmaceuticals, endometriosis
Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023
Clinical Trials Arena
Mon, 10/31/22 - 10:37 am
Tags:
clinical trials, systemic lupus erythematosus, AbbVie, ABBV-509, Eli Lilly, LY3471851, Merck KGaA, M5049, Swedish Orphan Biovitrum, emapalumab
AbbVie sheds autoimmune disease drug in blow to partner Inventiva
Pharmaphorum
Mon, 10/31/22 - 10:21 am
Tags:
AbbVie, autoimmune disease, Inventiva, cedirogant
AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now
Endpoints
Sun, 10/30/22 - 04:22 pm
Tags:
AbbVie, Humira, patents, biosimilars, earnings, patent cliff
AbbVie Gains Access to Pulmonary Fibrosis Antibody with $225M DJS Buy
BioSpace
Thu, 10/20/22 - 11:29 pm
Tags:
AbbVie, M&A, DJS Antibodies, pulmonary fibrosis, antibodies
What Pharma Companies Can Expect From the Influx of Humira Biosimilars
Drug Channels
Fri, 10/14/22 - 10:15 am
Tags:
AbbVie, Humira, biosimilars, Amgen, Amjevita
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
Fierce Pharma
Wed, 10/12/22 - 11:00 am
Tags:
BeiGene, AbbVie, JNJ, Imbruvica, blood cancers, Brukinsa
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
Tags:
biopharma stocks, AbbVie, Alnylam, AstraZeneca, Biogen, CRISPR Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, GSK, Intellia Therapeutics, Regeneron, Roche, Sanofi, Sarepta Therapeutics
BioSpace Layoff Tracker 2022: Cyclerion, OncoSec Implement Restructuring Initiatives
BioSpace
Fri, 10/7/22 - 10:45 am
Tags:
layoffs, Cyclerion, OncoSec, Exicure, AbbVie, Bristol Myers Squibb, Palisade Bio, ObsEva, Rubius Therapeutics, Novartis, Finch Therapeutics
Q3 2022: Layoffs Continue, Alzheimer’s Soars and Accelerated Approvals Fall
BioSpace
Mon, 10/3/22 - 11:33 pm
Tags:
layoffs, Vesalius Therapeutics, AbbVie, Bristol Myers Squibb, Palisade Bio, IBV, Zymergen
Where Will AbbVie Be in 3 Years?
Motley Fool
Fri, 09/30/22 - 10:50 am
Tags:
AbbVie, Humira, biosimilars, Rinvoq, Skyrizi, Vraylar
As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company
Endpoints
Thu, 09/29/22 - 10:02 am
Tags:
Idera Pharmaceuticals, AbbVie, Aceragen, M&A
AbbVie and BMS slash 360 jobs in California, the latest in a streak of biopharma layoffs
Fierce Pharma
Sun, 09/18/22 - 10:45 pm
Tags:
AbbVie, Bristol Myers Squibb, layoffs, California
AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved
Endpoints
Tue, 09/13/22 - 08:06 pm
Tags:
AbbVie, Allergan, Botox, DTC ads, Daxxify, Revance Therapeutics
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?
Fierce Pharma
Tue, 09/13/22 - 08:03 pm
Tags:
Novartis, FDA, Cosentyx, AbbVie, Humira, hidradenitis suppurativa
Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?
Endpoints
Thu, 09/8/22 - 11:04 am
Tags:
Revance Therapeutics, FDA, Daxxify, aesthetics, AbbVie, Botox

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.